Articolul precedent |
Articolul urmator |
381 3 |
Ultima descărcare din IBN: 2023-09-08 11:09 |
SM ISO690:2012 ANANCO, Alexandru, DIUG, Eugen, CIOBANU, Nicolae, GURANDA, Diana, CIOBANU, Cristina, ANTON, Mihail. Monoclonal antibodies in SARS-CoV-2 infection therapy. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 443. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
Pag. 443-443 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Immunotherapy has its potential in the treatment of various infectious diseases. Monoclonal antibodies (mAbs), in particular, represent a relatively new approach in the therapy of SARS-CoV-2 infection. Objective of the study. Description of mAbs as antiviral drugs in the treatment of SARS-CoV-2 infection. Material and Methods. The main sources of information on the results of research on the use of monoclonal antibodies in the treatment of SARS-CoV-2 infection were selected. Results. The first signs of efficacy in the treatment of SARS-CoV-2 infection was the use of convalescent plasma. Favorable preliminary results have led to the development of neutralizing mAbs derived from convalescent patients. At different stages of clinical investigations are about 14 AMC as antiviral drugs, such as: VIR-7831; LY-CoV555; BGB-DXP593; REGN-COV2 - being a combined product (imdevimab and casirivimab) and is being investigated for the treatment and prevention of SARS-CoV-2 infection. This drug has been approved by the MMDA in the Republic of Moldova for phase 3 clinical trials, being promising effective against mutant viral strains. Conclusion. Different stages of clinical research are a number of mAbs, as antiviral drugs, for the treatment of patients with COVID-19, as well as for the prevention of SARS-CoV-2 infection. |
||||||
Cuvinte-cheie convalescent plasma, monoclonal antibodies, SARS-CoV-2, clinical exams, plasmă convalescentă, anticorpi monoclonali, SARS-CoV-2, investigații clinice |
||||||
|